Free Trial

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Pfizer Inc. stock logo
PFE
Pfizer
$24.79
+0.5%
$24.87
$20.92
$29.17
$140.26B0.5558.97 million shs27.40 million shs
Elon Musk's Next Move Cover

Explore Elon Musk’s boldest ventures yet—from AI and autonomy to space colonization—and find out how investors can ride the next wave of innovation.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Pfizer Inc. stock logo
PFE
Pfizer
-0.16%+1.88%+2.30%-0.44%-14.50%
CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Pfizer Inc. stock logo
PFE
Pfizer
$24.79
+0.5%
$24.87
$20.92
$29.17
$140.26B0.5558.97 million shs27.40 million shs
Elon Musk's Next Move Cover

Explore Elon Musk’s boldest ventures yet—from AI and autonomy to space colonization—and find out how investors can ride the next wave of innovation.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Pfizer Inc. stock logo
PFE
Pfizer
-0.16%+1.88%+2.30%-0.44%-14.50%
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Pfizer Inc. stock logo
PFE
Pfizer
2.39
Hold$28.1313.48% Upside

Current Analyst Ratings Breakdown

Latest PFE Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
10/10/2025
Pfizer Inc. stock logo
PFE
Pfizer
Morgan Stanley
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Lower Price TargetEqual Weight$33.00 ➝ $32.00
10/8/2025
Pfizer Inc. stock logo
PFE
Pfizer
Weiss Ratings
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Reiterated RatingHold (C-)
10/3/2025
Pfizer Inc. stock logo
PFE
Pfizer
Bank of America
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Boost Price TargetNeutral$28.00 ➝ $30.00
10/1/2025
Pfizer Inc. stock logo
PFE
Pfizer
UBS Group
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Reiterated RatingNeutral$28.00
9/27/2025
Pfizer Inc. stock logo
PFE
Pfizer
Weiss Ratings
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Reiterated RatingHold (C-)
8/6/2025
Pfizer Inc. stock logo
PFE
Pfizer
Citigroup
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Boost Price TargetNeutral$25.00 ➝ $26.00
8/6/2025
Pfizer Inc. stock logo
PFE
Pfizer
Morgan Stanley
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Boost Price TargetEqual Weight$32.00 ➝ $33.00
8/6/2025
Pfizer Inc. stock logo
PFE
Pfizer
Bank of America
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Boost Price TargetNeutral$27.00 ➝ $28.00
(Data available from 10/24/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Pfizer Inc. stock logo
PFE
Pfizer
$63.63B2.21$4.39 per share5.65$15.62 per share1.59
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Pfizer Inc. stock logo
PFE
Pfizer
$8.03B$1.8813.188.180.8216.84%21.42%9.12%11/4/2025 (Estimated)

Latest PFE Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
11/4/2025Q3 2025
Pfizer Inc. stock logo
PFE
Pfizer
$0.79N/AN/AN/A$16.94 billionN/A
8/5/2025Q2 2025
Pfizer Inc. stock logo
PFE
Pfizer
$0.58$0.78+$0.20$0.51$13.43 billion$14.65 billion
CompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive Growth
Pfizer Inc. stock logo
PFE
Pfizer
$1.726.94%N/A91.49%16 Years

Latest PFE Dividends

AnnouncementCompanyPeriodAmountYieldEx-Dividend DateRecord DatePayable Date
10/9/2025
Pfizer Inc. stock logo
PFE
Pfizer
quarterly$0.436.82%11/7/202511/7/202512/1/2025
(Data available from 1/1/2013 forward)
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
Pfizer Inc. stock logo
PFE
Pfizer
0.65
1.16
0.85

Institutional Ownership

CompanyInstitutional Ownership
Pfizer Inc. stock logo
PFE
Pfizer
68.36%

Insider Ownership

CompanyInsider Ownership
Pfizer Inc. stock logo
PFE
Pfizer
0.06%
CompanyEmployeesShares OutstandingFree FloatOptionable
Pfizer Inc. stock logo
PFE
Pfizer
81,0005.69 billion5.68 billionOptionable

Recent News About These Companies

Why Pfizer's Headwinds May Already Be In The Price
Pfizer Inc. $PFE Shares Acquired by FSM Wealth Advisors LLC
2 Safer High-Yield Stocks That Can Pay Boomers for Life
Ethic Inc. Boosts Stock Holdings in Pfizer Inc. $PFE

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

View All Headlines
Pfizer stock logo

Pfizer NYSE:PFE

$24.78 +0.12 (+0.47%)
Closing price 03:59 PM Eastern
Extended Trading
$24.78 0.00 (0.00%)
As of 07:59 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Pfizer Inc. discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands. It also provides medicines and vaccines in various therapeutic areas, such as biosimilars for chronic immune and inflammatory diseases under the Xeljanz, Enbrel, Inflectra, Litfulo, Velsipity, and Cibinqo brands; amyloidosis, hemophilia, endocrine diseases, and sickle cell disease under the Vyndaqel family, Oxbryta, BeneFIX, Somavert, Ngenla, and Genotropin brands; sterile injectable and anti-infective medicines under the Sulperazon, Medrol, Zavicefta, Zithromax, and Panzyga brands; and biologics, small molecules, immunotherapies, and biosimilars under the Ibrance, Xtandi, Inlyta, Bosulif, Mektovi, Padcev, Adcetris, Talzenna, Tukysa, Elrexfio, Tivdak, Lorbrena, and Braftovi brands. In addition, the company involved in the contract manufacturing business. It serves wholesalers, retailers, hospitals, clinics, government agencies, pharmacies, individual provider offices, retail pharmacies, and integrated delivery systems. The company has collaboration agreements with Bristol-Myers Squibb Company; Astellas Pharma US, Inc.; Merck KGaA; and BioNTech SE. Pfizer Inc. was founded in 1849 and is headquartered in New York, New York.